共 93 条
[1]
Ross DS(2016)2016 American Thyroid Association guidelines for diagnosis and Management of Hyperthyroidism and Other Causes of thyrotoxicosis Thyroid 26 1343-1421
[2]
Burch HB(2010)Current and emerging treatment options for Graves' hyperthyroidism Ther Clin Risk Manag 6 29-40
[3]
Cooper DS(2012)The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0 J Nucl Med 53 1633-1651
[4]
Greenlee MC(2005)Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery Thyroid 15 1279-1286
[5]
Laurberg P(2007)Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science? Eur J Nucl Med Mol Imaging 34 1129-1130
[6]
Maia AL(2009)Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism Nucl Med Commun 30 160-168
[7]
Abraham P(2007)Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials BMJ 334 514-1509
[8]
Acharya S(2007)Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new? Eur J Nucl Med Mol Imaging 34 1504-79
[9]
Silberstein EB(2010)Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation Phys Med 26 71-689
[10]
Alavi A(2006)What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism? Clin Nucl Med 31 688-170